Walid M. Awni,Menon Rajeev M.,Wang Tianli,Liu Wei,Dutta Sandeep,Bernstein Barry M.,Andrew L. Campbell,Lin Chih-Wei,Podsadecki Thomas J.
申请号：
NZ63178914
公开号：
NZ631789A
申请日:
2014.03.14
申请国别(地区):
NZ
年份:
2018
代理人:
摘要：
Disclosed is the use of at least two direct acting antiviral agents (DAAs) and ribavirin for the manufacture of a medicament for the treatment of Hepatitis C virus (HCV) in an HCV patient, wherein said treatment does not include interferon, and wherein said at least two DAAs comprise: Compound 1 (glecaprevir) or a pharmaceutically acceptable salt thereof, and Compound 2 (Pibrentasvir) or a pharmaceutically acceptable salt thereof.
